IDYA
Price
$21.58
Change
-$0.51 (-2.31%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
1.89B
24 days until earnings call
RCUS
Price
$9.14
Change
-$0.27 (-2.87%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
968.85M
12 days until earnings call
Interact to see
Advertisement

IDYA vs RCUS

Header iconIDYA vs RCUS Comparison
Open Charts IDYA vs RCUSBanner chart's image
IDEAYA Biosciences
Price$21.58
Change-$0.51 (-2.31%)
Volume$9.21K
Capitalization1.89B
Arcus Biosciences
Price$9.14
Change-$0.27 (-2.87%)
Volume$6.58K
Capitalization968.85M
IDYA vs RCUS Comparison Chart in %
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. RCUS commentary
Jul 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Hold and RCUS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 19, 2025
Stock price -- (IDYA: $22.09 vs. RCUS: $9.42)
Brand notoriety: IDYA and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 62% vs. RCUS: 90%
Market capitalization -- IDYA: $1.89B vs. RCUS: $968.85M
IDYA [@Biotechnology] is valued at $1.89B. RCUS’s [@Biotechnology] market capitalization is $968.85M. The market cap for tickers in the [@Biotechnology] industry ranges from $293.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileRCUS’s FA Score has 0 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, both IDYA and RCUS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 3 TA indicator(s) are bullish while RCUS’s TA Score has 5 bullish TA indicator(s).

  • IDYA’s TA Score: 3 bullish, 4 bearish.
  • RCUS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RCUS is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а -3.11% price change this week, while RCUS (@Biotechnology) price change was -1.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.49%. For the same industry, the average monthly price growth was +13.01%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

IDYA is expected to report earnings on Nov 11, 2025.

RCUS is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($1.89B) has a higher market cap than RCUS($969M). IDYA YTD gains are higher at: -14.047 vs. RCUS (-36.736). IDYA has higher annual earnings (EBITDA): -356.46M vs. RCUS (-377M). RCUS has more cash in the bank: 997M vs. IDYA (693M). IDYA has less debt than RCUS: IDYA (26M) vs RCUS (60M). RCUS has higher revenues than IDYA: RCUS (141M) vs IDYA (7M).
IDYARCUSIDYA / RCUS
Capitalization1.89B969M195%
EBITDA-356.46M-377M95%
Gain YTD-14.047-36.73638%
P/E RatioN/AN/A-
Revenue7M141M5%
Total Cash693M997M70%
Total Debt26M60M43%
FUNDAMENTALS RATINGS
IDYA vs RCUS: Fundamental Ratings
IDYA
RCUS
OUTLOOK RATING
1..100
589
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
52
Fair valued
PROFIT vs RISK RATING
1..100
79100
SMR RATING
1..100
9497
PRICE GROWTH RATING
1..100
5760
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCUS's Valuation (52) in the Pharmaceuticals Major industry is in the same range as IDYA (61) in the null industry. This means that RCUS’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (79) in the null industry is in the same range as RCUS (100) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to RCUS’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as RCUS (97) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to RCUS’s over the last 12 months.

IDYA's Price Growth Rating (57) in the null industry is in the same range as RCUS (60) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to RCUS’s over the last 12 months.

RCUS's P/E Growth Rating (99) in the Pharmaceuticals Major industry is in the same range as IDYA (100) in the null industry. This means that RCUS’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYARCUS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 1 day ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 10 days ago
77%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
Bearish Trend 8 days ago
77%
Bearish Trend 12 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 1 day ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 1 day ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SUTZX16.550.17
+1.04%
AB Sustainable US Thematic Z
MTCJX72.140.56
+0.78%
MFS Technology R4
FDERX23.440.18
+0.77%
Federated Hermes Equity Income R
MXCCX7.500.04
+0.54%
Federated Hermes Max-Cap Index C
HGICX49.290.16
+0.33%
Hartford Core Equity C

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-0.27%
IMNM - IDYA
61%
Loosely correlated
+8.07%
CGON - IDYA
60%
Loosely correlated
+9.13%
XENE - IDYA
59%
Loosely correlated
+1.58%
CRNX - IDYA
59%
Loosely correlated
+3.51%
NRIX - IDYA
59%
Loosely correlated
-2.66%
More

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with XNCR. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
+1.73%
XNCR - RCUS
51%
Loosely correlated
+2.72%
IDYA - RCUS
49%
Loosely correlated
-0.27%
ACLX - RCUS
48%
Loosely correlated
+0.35%
TRDA - RCUS
47%
Loosely correlated
+0.16%
IMNM - RCUS
47%
Loosely correlated
+8.07%
More